Healthcare Professionals
Lupin Neurosciences is committed to working with Healthcare Professionals to develop strategies that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.
NaMuscla®
NaMuscla® is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
From SmPC, latest renewal date 09.08.2023
Please select your country of residence for locally approved package leaflets:
EMA SmpC
22.01.2026
MHRA SmpC 83 mg for UK
26.01.2026
MHRA SmpC 167 mg for UK
14.01.2026